A Study of a Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular Hypertension

This study has been completed.

First Received: April 10, 2006 Last Updated: February 29, 2008 History of Changes

Sponsored by:	Alcon Research
Information provided by:	Alcon Research
ClinicalTrials.gov Identifier:	NCT00314158

Purpose

The purpose of this study is to determine whether a glaucoma therapy is safe and effective in treating patients with open-angle glaucoma or ocular hypertension.

Condition	Intervention	Phase
Open-Angle Glaucoma Ocular Hypertension	Drug: Brinzolamide 1%/Timolol 0.5%, Brinzolamide 1%, Timolol 0.5%	Phase III

Study Type:	Interventional
Study Design:	Treatment, Randomized, Double-Blind, Active Control, Parallel Assignment, Safety/Efficacy Study

Resource links provided by NLM:

Genetics Home Reference related topics: early-onset glaucoma

MedlinePlus related topics: Glaucoma High Blood Pressure

Drug Information available for: Timolol Timolol maleate Azopt

U.S. FDA Resources

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Over 18 with open-angle glaucoma

Exclusion Criteria:

Under 18

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00314158

Locations

United States, Texas
United States Investigative Sites
Fort Worth, Texas, United States, 76134

Sponsors and Collaborators

Alcon Research

More Information

No publications provided

Study ID Numbers:	C-05-24
Study First Received:	April 10, 2006
Last Updated:	February 29, 2008
ClinicalTrials.gov Identifier:	NCT00314158 History of Changes
Health Authority:	United States: Food and Drug Administration

Study placed in the following topic categories:

Neurotransmitter Agents
Adrenergic Agents
Brinzolamide
Eye Diseases
Vascular Diseases
Cardiovascular Agents
Antihypertensive Agents
Carbonic Anhydrase Inhibitors

Glaucoma
Glaucoma, Open-Angle
Adrenergic beta-Antagonists
Adrenergic Antagonists
Timolol
Anti-Arrhythmia Agents
Ocular Hypertension
Hypertension

Additional relevant MeSH terms:

Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Adrenergic Agents
Brinzolamide
Eye Diseases
Physiological Effects of Drugs
Vascular Diseases
Enzyme Inhibitors
Cardiovascular Agents
Antihypertensive Agents
Pharmacologic Actions

Carbonic Anhydrase Inhibitors
Glaucoma
Therapeutic Uses
Glaucoma, Open-Angle
Adrenergic beta-Antagonists
Cardiovascular Diseases
Adrenergic Antagonists
Anti-Arrhythmia Agents
Timolol
Hypertension
Ocular Hypertension

ClinicalTrials.gov processed this record on July 02, 2009